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Abstract. The function of neurofilaments, the major
component in large myelinated neurons, is not well under-
stood even though they were discovered as structures over
100 years ago. Recent studies have suggested that neuro-
filaments are closely related to many neurodegenerative
diseases, such as amyotrophic lateral sclerosis, Parkinson
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disease Alzheimer disease, and diabetes. Using in vitro
assays, cultures and transgenic mice, these studies pro-
vided new insights into neurofilament function. The
function of each subunit, the relationship of neurofila-
ments with other cytoskeletal elements and their clinical
significance are topics of increasing attention.
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Introduction
Neurofilaments (NFs) are intermediate filaments of neu-
rons that are considered to add rigidity, tensile strength
and possibly intracellular transport guidance to axons and
dendrites [1].  Exclusively expressed in neurons, NFs are
members of the cytoskeleton proteins that act together to
form and maintain cell shape and facilitate the transport
of particles and organelles within the cytoplasm. 
Based on differences in diameter and protein components,
cytoskeletal polymers are classified into three groups:
microtubules (MTs) (~24 nm), microfilaments (MFs)
(~6–8 nm) and intermediate filaments (IFs) (~10 nm).
MTs, which are predominatly composed of tubulin, are
responsible for maintaining cell shape, organelle and
vesicle movement, and the formation of spindle fibers
during mitosis. MFs, which are composed predominantly
of actin, are responsible for cellular movement, muscle
* Corresponding authors.
contraction, mechanical strength and cytokinesis. IFs are
composed of different proteins and are prominent in cells
that withstand mechanical stress. Moreover, IFs are the
most insoluble components of the cells. In contrast to the
similarity in polymer composition of MTs and MFs in all
tissues, IF polymers differ in different tissues and differ-
ent cells. Based on molecular structural homology, five
types of IFs have been identified, and NFs belongs to type
IV IFs (table 1). 
In this review, current knowledge about NF history, gen-
eral properties, expression, assembly, transport, post-
translational modification, degradation, functions, trans-
genic mouse models, related diseases and clinical impli-
cations will be summarized
History
As early as the 1830s, neuronal networks had already
been described [2, 3]. The discovery of the silver staining
method in the late 19th century resulted in a clear vision
of NFs [4, 5], which also led to the characterization of
neurofibrillary tangles and senile plaques by Alois
Alzheimer [6]. With the development of electron mi-
croscopy after 1931 (Max Knoll and Ernst Ruska in Ger-
many), the molecular structures of NFs were further de-
fined as filaments ~10 nm in diameter and present exclu-
sively in neuronal cells. For a long time, it was known that
NFs are involved in several neuronal diseases, and in the
past decade, NFs have been linked to more human di-
seases, which will be discussed here. With the develop-
ment of specific antibodies, transgenic animal models
and molecular genetic methodologies, studies of NFs 
advanced to the molecular level.
General properties
Together with peripherin, a-internexin and nestin, NFs
belong to type IV IFs and share common sequence struc-
tures (table 1). A central a-helical rod domain of about
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310 amino acids is flanked by a globular N-terminal
region and non – a-helical carboxy-terminal side-arm
domains. The central rod domains, including regions 1a,
1b, and 2, contain highly conserved motifs and every
seventh residue is hydrophobic, which facilitates the for-
mation of a-helical coiled-coil parallel homodimers or
heterodimers. A linker region aligns the hydrophobic
residues. These properties are characteristic of the IFs
and are essential for their proper assembly (fig. 1). 
NFs are composed of three subunits, and these subunits
are defined by their molecular weight: NF-L (light), 
NF-M (medium) and NF-H (heavy), which are 60 kDa,
100 kDa and 110 kDa, respectively, as predicted from 
the DNA sequences [7]. These subunits exhibit higher
molecular weights on SDS-polyacrylamide gel electro-
phoresis (PAGE): 68 kDa, 160 kDa and 205 kDa, respec-
tively, because of the enriched negatively charged amino
acids (glutamic acid) in their sequences and post-transla-
tional modifications such as phosphorylation and glyco-
sylation [7, 8]. NFs constitute the most abundant struc-
Table 1. Types of IFs. IFs include five defined types and other undefined types. Their molecular weights are varied, and they are found 
in different cell types. Neurofilament subunits belong to type IV IFs.
Type Name Molecular weight Cell
I acid keratins 40–60 kDa epithelial
II basic keratins 50–70 kDa epithelial
III desmin 50–70 kDa muscle
GFAP astroglia
peripherin/vimentin mesenchymal, tissue cultured cells
IV NF-L, NF-M, NF-H 50–200 kDa neuronal
a-internexin immature neuronal
nestin CNS stem cells
V nuclear lamins 60–70 kDa most other undefined types
Figure 1. Comparison of the structures of NF subunits and other type IV filaments. The NF subunits and other type IV IFs all include a-
helical rod domain and are varied in N- and C-termini. A unique character of NF-M and NF-H is that their C-termini have multiple KSP
repeats which are heavily phosphorylated. Also shown here, are posttranslational modifications, including phosphorylation and glycosyla-
tion on NF subunits (summarized from [7, 8, 11]).
tures in large myelinated neurons, and can account for
13% of total proteins and 54% of the Triton-insoluble
proteins in some neurons [9, 10]. More detailed descrip-
tion of all IF structures is recorded in several reviews 
[7, 11, 12].
Expression
The three NF subunits are expressed at distinct stages of
vertebrate development, triggered by neuron differentia-
tion [13–15]. Initially, NF-L is expressed at the beginning
of neuronal differentiation and overlaps with the expres-
sion of a-internexin and peripherin [14, 16]. NF-M is 
expressed shortly after with the emergence of neurite
formation, whereas NF-H is expressed later when axonal
radial growth is required for nervous system maturation
[14, 16].  
The genes coding for human NFs include NEFL gene
(NF-L protein), NEFM gene (NF-M protein), and NEFH
gene (NF-H protein). NEFL and NEFM genes are closely
located, at chromosome 8, 8p21 [17, 18]; NEFH gene is
at chromosome 22, 22q12.2 [19]. Expression of messen-
ger RNAs (mRNAs) of NF subunits is consistent with
their protein levels in cultured neuroblastoma cells, and
NF-L and NF-M mRNAs are expressed several days be-
fore the appearance of NF-H mRNA in these cells [20]. It
appears that the NF-L and NF-M genes are coordinately
regulated, while the NF-H gene is expressed indepen-
dently later.  
Assembly
NF assembly is not clearly understood yet, though in vivo
studies have demonstrated that NFs are obligate hetero-
polymers requiring NF-L to form a proper polymer with
either NF-M or NF-H [21, 22]. NF formation is believed
to start with the dimerization of NF-L with either NF-M
or NF-H subunits. The highly conserved rod domains 
of the NF subunits are coiled together in a head-to-tail
fashion to form a dimer. Two coiled dimers overlap with
each other in an anti-parallel, half-staggered manner,
forming the tetramers. Finally, eight tetramers are packed
laterally and longitudinally together in a helical array,
forming a ropelike 10-nm filament [11, 23–25]. In the
cross section of NF, there are ~32 molecules, though the
number may change in different stages or conditions [26].
Theoretically, before the synthesis of NF-H, NFs are only
composed of NF-L and NF-M [27]. The C-termini of 
NF-M and NF-H are not in the coils, but they form the
side arms of the NFs [28] (fig. 2).
NF-L is essential for the precise assembly of NFs [21, 22,
29]. NF-M participates in the formation of cross-bridges,
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Figure 2. Schematic model of NF assembly. In the NF assembly process, two NF subunits (NF-L, and either NF-H or NF-M) form head-
to-tail coiled-coil dimers, anti-parallel half-staggered tetramers, protofilaments, and 10-nm NFs. There are ~32 molecules in the cross-
section, and hyperphosphorylated side arms formed by the C-termini of NF-H and NF-M stick out of the stem of the filament.
stabilization of the filament network and longitudinal 
extension [30–33]. NF-H also contributes to the forma-
tion of cross-bridges and may interact with micro-
tubules/microfilaments and other cytoskeletal elements
[32–34]. However, recent studies showed NF-H side arms
are not critical for radial growth of the axons [12, 35]. 
NF-M and NF-H by themselves do not form filaments
in vivo [21, 22, 29, 36], while NF-L can form homopoly-
mers in vitro  [37, 38] and in cells transfected with NF-L
[39], but not in mice [33]. Although NFs are obligate
heteropolymers in vivo in rodents, this may not be the
case in humans [39]. 
In contrast to NF subunits, a-internexin and peripherin
self-assemble into homopolymers and co-assemble with
NF subunits [40–42]. Many central nervous system (CNS)
neurons also contain varying levels of a-internexin, a
type IV IF subunit [43] expressed abundantly in embryo-
nic neurons but at lower levels postnatally [44, 45]. Al-
though a-internexin co-localizes with NFs and forms
filaments with each of the triplet proteins invivo [21], the
composition of the filaments is still not known in vivo.
Peripherin, a type III IF, is expressed in lower motor, auto-
nomic, and sensory neurons and also co-assembles with
the NF subunits [41, 42]. 
Transport
After their synthesis in the perikarya, neurofilament pro-
teins (NFPs) are quickly translocated into the axons and
assemble into filamentous structures. In radioisotopic 
labeling studies, neurofilament proteins move at a rate 
of 0.2–1 mm/day in the axon with the slow components,
whereas other organelles such as membrane vesicles can
move at the much faster rate of 200–400 mm/day [46]. 
The mechanism by which IF proteins are transported has
been a topic of debate for many years due to the lack of
techniques in determining the form in which these pro-
teins are transported. The polymer hypothesis suggests that
NF subunits are assembled and transported mainly as poly-
meric structures [47, 48], whereas the subunit hypothesis
argues that the NF proteins are transported down the axon
as individual subunits or small oligomers [49–52]. Photo-
bleaching experiments with fluorescent-tagged proteins
support the subunit hypothesis, in which the bleached
axonal segment remained stationary with gradual recovery
of its fluorescence without any obvious directionality
[53]. Recently, using green fluorescent protein (GFP)-
tagged NF subunits and live cell imaging, two research
groups found a fast transport of NF polymers down the
axon at a rate up to 2 mm/s [54, 55] which was interrupted
by prolonged pauses and resulted in a net slow velocity. 
Therefore, the current understanding of NF transport is
that they are transported bi-directionally in the axon along
microtubules through common motors such as dynein and
kinesin. The average slow rate of NF movement is because
NF structures spend most of their time (>99%) pausing 
in the axon. The pauses might be the result of a lack of
transient interactions between motors and NF structures.
Consistent with this model, the kinesin motor was found
to co-localize with the motile NF pool in the squid giant
axon [56]. In addition, phosphorylation of NFPs (mainly
on NF-H) resulted in their dissociation from the kinesin
motor, thereby decreasing their transport speed [57].
Posttranslational modifications
Two major posttranslational modifications are involved
in the formation and functions of NFs, phosphorylation
and glycosylation.
Phosphorylation
NFP phosphorylation is topographically regulated within
neurons. Recent studies show that phosphorylation of the
NF subunits plays a critical role in regulation of filament
translocation, formation and function. It is also involved
in the pathogenesis of some related neurodegenerative
diseases. 
Almost all (>99%) of the assembled NFs in myelinated
internodal regions are known to be stoichiometrically
phosphorylated in the Lys-Ser-Pro (KSP) repeat domains
[58]. In contrast, the KSP repeats of NFPs in cell bodies,
dendrites and nodes of Ranvier are less phosphorylated.
The unphosphorylated NFs only account for ~1% of NFs
in the neuron as judged by NF density and the relative
volumes of the respective compartments [58–60]. 
Although other Ser/Thr motifs are also phosphorylated,
most phosphorylation sites are in KSP motifs of the tail
domains of NF-M and NF-H. It is consistent with the stud-
ies done by Jaffe et al. [61] showing that 33 out of 38 phos-
phorylation sites of NF-H C-terminus are at KSP motifs.
Normally NF-M and NF-H undergo posttranslational hy-
perphosphorylation upon entry into the axons. The phos-
phorylation of NF-M occurs at embryonic day 13 (E13)
in mouse spinal cord neurons, and the NF-M level and 
its phosphorylation demonstrate a polarized character in
the growing axons: a proximal-distal gradient with most
intense expression in axons of peripheral nerves, and little
or no detection in perikarya and dendrites [62–65]. NF-M
and NF-L levels reach adult values at E15 when a low
level of a mixture of non-phosphorylated and phosphory-
lated NF-H is first detected in brain and spinal cord.
Phospho-NF levels are increased in brain and spinal cord
axons after E17 and are displayed in a gradient fashion
along the axon, proximally to distally, as if responding 
to signals from terminals [15, 16]. Myelination also pro-
motes NFP phosphorylation and radial growth of axons,
while demyelination of motor neurons causes loss of
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phosphorylation on NF-M and NF-H [59]. This may be due
to regulation of relevant phosphatases and kinases. 
In vivo phosphorylation of NFPs in axons is a slow pro-
cess [66]. The explanation of this includes the slow trans-
port of NF proteins into the axon, delayed activation of
local kinases or more possibly the inaccessibility of phos-
phate acceptor sites because of a ‘closed’ conformation 
of the assembled polymer. The topologically sequential
phosphorylation may be due to the sequential opening of
the next accessible phosphorylation site after the pre-
phosphorylation of the other sites (fig. 3). 
NFP phosphorylation plays multiple roles; its major
function is believed to be the regulation of axonal radial
growth. Extensive phosphorylation of KSP repeats in the
tail domain of NF-M and NF-H occurs primarily in axons
[15, 62, 67]. This results in side-arm formation, increased
interneurofilament spacing, radial growth of axons and
increased conduction velocity [36, 59, 68]. Phosphoryla-
tion of KSP motifs triggered by a Schwann cell signal has
been proposed as a key determinant of local control of 
NF accumulation, interfilament spacing and radial growth
of myelinated axons [59, 64, 68–70]. Recent studies using
NF-H null mice, or mice transfected with a NF-H tailless
mutant, suggest that neither NF-H nor its phosphorylated
tail is essential for determining neuronal caliber [71, 72].
These studies, together with those using NF-M knockout
mice [31, 32, 73], indicate that NF-M plays a more pro-
found role in regulating the axonal diameter. Moreover,
alternation of NF-M and NF-H tail domain phosphoryla-
tion is associated with the pathology seen in neurode-
generative disorders such as amyotrophic lateral sclerosis
(ALS) and Alzheimer disease (AD), in which tail domain
phosphorylation and NF accumulation occur abnormally
in perikarya [74–77].
Recent studies show that phosphorylation also plays a
critical role in inhibiting NF assembly in the perikaryon,
which explains why NFPs only form filaments in axons
[15, 62, 67]. N-terminal head domain phosphorylation by
protein kinase A (PKA) at Ser55 in NF-L or Ser46 in NF-M
inhibits assembly of NF subunits into a heteropolymer in
vitro and in vivo [78–82]. Consistent with these studies,
phosphorylation/dephosphorylation of Ser55 and Ser57 in
NF-L regulates NF assembly and disassembly [83, 84].
Prevention of NF-L Ser55 dephosphorylation through a
Ser-to-Asp mutation, mimicking permanent phosphory-
lation, resulted in pathological accumulation of NF aggre-
gates in brain neuronal cell bodies [84]. These studies
suggested that the transient head domain phosphorylation
in cell bodies elaborately regulates NFP polymerization
and filament formation in perikarya [22, 85]. Moreover,
dephosphorylation of these sites is prerequisite for NFP
assembly in axons.
In addition to the axonal assembly, phosphorylation of
head domain sites of NF-M also regulates phosphoryla-
tion of the tail domain KSP repeats in perikarya and
axons. Zheng et al. [86] found that NF-M head domain
phosphorylation by PKA decreases Erk1/2 kinase acti-
vated tail domain phosphorylation in vitro and in vivo, and
mutant NF-M (Ser1, 23, 46 to Ala) diminished this regula-
tion in transfected NIH3T3 cells. These findings are con-
sistent with the hypothesis that transient phosphorylation
of NF-M head domains inhibits phosphorylation of tail
domains and poses a new mechanism for topographic
regulation of NFP phosphorylation in neurons. So tran-
sient phosphorylationof head domain motifs of NF-L and
NF-M by PKA and PKC in cell bodies can prevent NF 
assembly and C-terminal phosphorylation in perikarya
[22, 78, 80, 81, 85], protecting the neuron from abnormal 
accumulation of phosphorylated NFP aggregates in cell
bodies. In fact, few NFs are seen in cell bodies, and only
small oligomers can be detected, which suggests that 
consequential NF assembly is restricted to axons during
transport [87]. If this tight topographic regulation is 
altered by a variety of exogenous factors, then abnormal
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Figure 3. Regulatory functions of NF phosphorylation. N-terminal phosphorylation has both inhibitory and promotional effects for 
C-terminal phosphorylation in NFs, and N-terminal phosphorylation can also control NF translocation and assembly in axons.
NF assembly and tail domain phosphorylation would be
induced in cell bodies with severe pathological conse-
quences. As we know, in neurodegenerative diseases such
as ALS and AD, abnormally phosphorylated NFPs in the
cell bodies are the hallmark of the disease [12].
Phosphorylation of NFs may also slow down NF transport
within axon. It has been proposed that the heavily phos-
phorylated NF-H subunit detaches from the transport
carrier and resides in the axon for months, whereas less
phosphorylated subunits are transported at normal slow
axonal transport rates and have a short residence time in
the axon [88, 89]. Consistent with this hypothesis, studies
of complete deletion of NF-H, NF-M or both increase the
rate of transport of the remaining NF subunits in mouse
sciatic nerves [31–33, 90]. Moreover, in cultured optic
nerve axons, hypophosphorylated NF subunits have been
interpreted to undergo axonal transport more rapidly than
subunits more extensively phosphorylated at their tail
domains [91], and the C-terminal phosphorylation of 
the NF-H subunit correlates with decreased NF axonal 
transport velocity [92, 93]. But Rao et al. [35] constructed
NF-H tailless mice by an embryonic stem cell mediated
gene knock-in approach and showed the NF-H tail is
important neither for the axonal diameter nor the trans-
port rate. Ackerley et al. [94] argued with these results by
analyzing movement of GFP-tagged phosphorylation
mutants of NF-H in neurons, which supports a role for
NF-H side-arm phosphorylation as a regulator of NF 
transport. Most of the studies supports phosphorylation
of NF side arms regulating NF transport rates [69, 93, 
95, 96]. 
Glycosylation
In addition to phosphorylation, NFs are also modified
posttranslationally with O-linked N-acetylglucosamine
(O-GlcNAc) on serine and threonine residues [8], which
is the simplest protein modification with sugars [97].
Initially discovered from murine lymphocytes [98], this
modification has been found in all compartments of
eukaryotic cells [99]. The O-GlcNAc modification (O-
GlcNAcylation) is highly abundant and dynamic, similar
to phosphorylation [100–106]. 
NF-H, NF-M and NF-L are modified by O-GlcNAc in
vivo to stoichiometries of at least 0.3, 0.15 and 0.1 mol
GlcNAc/mol of protein at both termini [107] (fig. 1).
Although the stoichiometry of O-GlcNAcylation on iso-
lated NFPs is very low compared with phosphorylation,
it seems likely that only a subset of NF subunits is modi-
fied by O-GlcNAc, and the stoichiometry in those sub-
units is probably much higher. It is worth mentioning that
this O-GlcNAcylation most likely is a consensus of the
PX0-4(S/T) motif (X is usually a hydrophobic residue),
similar to the motifs used by proline-directed kinases and
phosphatases (X[S/T]PX or XP[S/T]X) [106]. 
The proximity or competition of the O-GlcNAcylation
sites to the phosphorylation sites in the head domain and
the importance of the head domain in NF assembly [108–
110] indicate that O-GlcNAcylation may also play a role
in NF assembly. This regulation could be exerted by either
direct or indirect (e.g. by affecting phosphorylation) in-
fluence on the structure of the head domain. It is possible
that O-GlcNAc is added to NFPs by O-GlcNAc transfer-
ase [101, 102] right after their synthesis and prior to 
assembly into filaments and transport into the distal part 
of axons and subsequently removed by an N-acetyl-b-D-
glucosaminidase [8]. 
By replacing phosphates with O-GlcNAc, the interaction
between NFs may switch from repulsive to associative,
leading to close packing of NFs, which happens in the
nodes of Ranvier. Therefore, it seems likely that organ-
ization of NFs is regulated by kinase/phosphatase [111,
112] and O-GlcNAc transferase/N-acetyl-b-D-glucos-
aminidase [101, 102, 113]. Dynamic O-GlcNAcylation
[105, 106] and phosphorylation [111] could therefore 
regulate proper NF assembly and dynamics, and abnor-
malities in either of them could contribute to some of the
motor neuron diseases in which NFs accumulate aber-
rantly [112, 114]. 
Degradation
Many neurons extend their axons over great distances, 
up to 1 m in humans, to form synapses with appropriate
receptor cells. To maintain the physiological functions of
the nerves, certain proteins need to have long lifetimes to
span the axon. NFPs are among them. In the transport
process NFP degradation is not detected. Pulse-labeling
experiments indicate that the cytoskeletal proteins are
metabolically stable during their passage through the
axon, and essentially all of these proteins complete the
trip to the axon terminus [115, 116]. So it is believed that
NFP degradation may only happen at synapses [117, 118],
where dephosphorylation of NFs by the protein phos-
phatase 2A (PP2A) precedes NF degradation, which also
indicates phosphorylation has a protective function in
protecting the NFPs from degradation [119]. At the axonal
terminus, the half residence time of NF is around 2 days
[120]. The disintegration of NFs during pathological con-
ditions is accounted for by the presence of calcium-acti-
vated protease (calpains) in the axoplasm [121, 122]. Cal-
pains can degrade many different proteins, including im-
portant axonal cytoskeletal proteins such as spectrin,
microtubule-associated protein-1, tau, tubulin and NFs,
as well as several protein constituents of myelin (e.g.
myelin basic protein, myelin-associated glycoprotein and
proteolipid protein) [123]. The breakdown and turnover
of NF could be accounted for by the activation of this pro-
tease in nerve terminals. It is possible that the recycling
of NF degradation products represents an important feed-
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back mechanism regulating NF production. The success
or failure of axonal regeneration may be determined by
intrinsic neuronal factors that control the production of
the axon cytoskeleton [122]. 
NFs synthesis was also detected in axons, but accounts
for less than 1% of total [124, 125], and the role of this
small amount of newly synthesized NFs is unknown.
Functions
The basic function of NF is supporting 
axonal structure
As a member of the cytoskeletal system, NFs work to-
gether with microtubules and microfilaments to enhance
structural integrity, cell shape, and cell and organelle
motility. The major function of NFs is to control the ax-
onal caliber, which is related to their phosphorylation
state. This is important since the speed of conductivity of
an impulse down the axon is proportional to its caliber.
NFs are particularly abundant in neurons with large-
diameter axons (>5 mM) such as those of periphery motor
neurons controlling skeletal muscle, where fast impulse
conduction velocities are crucial for proper functioning.
The first study of the role of NFs in caliber determination
came from analyses of a natural mutant quail in which 
the NF-L gene was disrupted [126–128]. Later studies of
transgenic mice lacking axonal NFs confirmed this role
[129], which will be discussed more in the section on
mouse models.
Detrimental effects of NF accumulations 
It is well known that accumulation of NFs is a general
hallmark for several neurodegenerative diseases. These
include amyotrophic lateral sclerosis (ALS), Alzheimer
disease (AD), Lewy bodies in Parkinson’s disease (PD),
progressive supranuclear palsy, Charcot-Marie-Tooth
disease, diabetic neuropathy and giant axonal neuropathy
[130–136]. 
The detrimental effect of these accumulations is seen
when the protein inclusions in axons mechanically block
the transportation of particles through the axon, which
will eventually lead to neuronal death [46, 124, 137].
Studies showed that abnormal accumulations of NFs in
the perikaryon of motor neurons can be induced by over-
expressing any of the three NF subunits. Increasing the
levels of NF-H or NF-M not only impairs NF transport
into the axon, but also inhibits dendritic arborization
[138–140]. Ma et al. [141] overexpressed human NF-L in
mice and reported the severe loss of neurons in the parietal
cortex and ventrobasal thalamus with age. Xu et al. [137]
showed transgenic mice overexpressing ~4-fold mouse
NF-L cause neuron degeneration and neuron loss, which
resembles the pathology of ALS. Recently, using cells
and mice overexpressing human NF-L, Sanelli et al. [142]
showed that the co-localization of copper/zinc superoxide
dismutase (SOD1) and neuronal nitric oxide synthase
(nNOS) to NF aggregates may cause sequestration of
nNOS in NF aggregates, which leads to enhanced NMDA-
mediated calcium influx that may cause neuron death in
ALS. These results provide new insights into why NF ag-
gregations are linked to neuronal death. All these studies
emphasize the importance of subunit stoichiometry for
correct NFP assembly and transport. 
Protective effects 
Other studies showed that NFPs have a protective effect
for neuronal survival. Couillard-Després et al. [143]
showed that crossing transgenic mice overexpressing
human NF-H and mice expressing a mutant superoxide
dismutase (SOD1G37R) linked to human ALS increase the
lifespan of the progeny by up to 65%. Another example of
protection by extra human NF-H came from the analysis
of doubly transgenic mice that overexpress both peri-
pherin and human NF-H transgenes [144]. The NF-H
overexpression completely rescued the peripherin-medi-
ated degeneration of motor neurons in vivo. The over-
expression of human NF-H shifted the intracellular local-
ization of peripherin from the axonal to the perikaryal
compartment of spinal motor neurons, which suggests
that the protective effect of extra human NF-H proteins 
in this situation partly come from the sequestration of 
peripherin into the perikaryon of motor neurons, thereby
abolishing the development of axonal IF inclusions that
might block transport. These findings illustrate again 
the importance of IF protein stoichiometry in formation,
localization and potential toxicity of neuronal inclusion
bodies. This is also supported by studies showing NFs
were not required for pathogenesis induced by mutant
SOD1, because in the absence of NF-L, with depletion of
NFs in axons, life span was extended by 15% in SOD1
mutant mice [145]. All these studies support a protective
effect for the depletion of axonal NFs or the accumulation
of NFPs in the cell perikaryon. 
Against this hypothesis, the disruption in one allele of
NFL gene in mutant SOD1 mice resulting in a 40%
decrease in axonal NF content and caliber of motor axons
but had no effect on disease severity and life span of
SOD1 mutant mice [146], which suggests that axonal
depletion of NF alone was not responsible for slowing
disease in mutant SOD1 mice. Their hypothesis is that
perikaryal NFs can alleviate the toxicity of mutant SOD1
by sequestering p25/Cdk5 complex and by acting as a
phosphorylation sink for deregulated kinase activity,
thereby reducing the potential toxicity of hyperphos-
phorylation of tau and of other Cdk substrates such as 
Rb [147, 148].
Another possible explanation of NFPs, protective func-
tion may relate to the normal function of these proteins.
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In ALS, AD and control brains, axonal NF displays the
most abundant carbonyl modifications in gray matter of
the CNS [149, 150]. The 205-kDa NF-H and, to a lesser
extent, the 160 kDa NF-M, displayed the majority of 
the adducts of the lipid peroxidation aldehyde product –
hydroxynonenal (HNE) in SODG85R mutant mice and
1–33 month normal aged mice [151]. The level of HNE
modification showed no difference with age in any cases.
These results also support the NF sequestration hypo-
thesis, where NFs take up toxic components, either p25/
Cdk5 complex or toxic products of oxidation or others,
consequently leading to protection of cells and mainten-
ance of physiological conditions [152] (fig. 4). 
Many questions still remain, such as how to reconcile
apparently conflicting functions of NFs. Resolution of
NF toxicity and protection requires understanding why
some NF knockout mice and NF transgenic mice are
completely normal even though they have perikaryal
inclusions for years, and what the initial cause(s) of the
degeneration of neurons is (are). In addition to investigat-
ing the perikaryal inclusions, some effort needs to be
made to determine the initial causes leading to inclusion
formation.
The possible function of KSP repeats
The prominent characteristic of NF-H/M is the multiple
KSP repeats in their C-termini, ~50 KSP repeats in NF-H
(~ 3–13 in NF-M) in many species. In human NF-H, there
are 43–44 KSP repeats separated by 3–5 amino acids, and
most of the serines in the KSP repeats are phosphorylated
in axons [153]. Hyperphosphorylation of KSP repeats in
the C-termini of NF-H/M may contribute to NF spacing due
to charge repulsion [59, 154], and also prevent protease de-
gradation during the long lifespan of these proteins [119].
Recent data from our group showed that lysine residues in
KSP repeats can be adducted by carbonyls of products of
oxidative stress, and the adduction is regulated by phos-
phorylation so that phosphorylated NF-H more readily
forms HNE adducts [151 and Q. Liu and G. Perry, un-
published data]. Selective absorption showed that lysine
residues are the major reactive sites for HNE adduction 
in NFs [151]. Most of the accessible lysine sites reside 
in the C-termini of NF-H and NF-M in the multiple KSP
repeats (human NF-H has 43–44 KSP repeats; human
NF-M has 12 KSP repeats). These findings are consistent
with another study that showed NFs are the major target
of the elevated oxidative stress produced in spinal cord
injury [155], and those showing carbonyl derivatives
from glycation are also elevated in axons [104]. 
These data provide new insight into the function of NFs
and the KSP repeats. During the lifespan of neurons,
NFPs, especially NF-H, are capable of assimilating stress-
related modifications/adducts to balance cellular condi-
tions, until they are degraded at the synapse or the modi-
fications are reversed in the cytoplasm (fig. 5). NFPs, the
major components in axons, may act as a sink for toxic
carbonyls, such as HNE. The extremely low ratio of reac-
tive species to NFPs, the reversibility of the modifica-
tions and the degradation of the modified NFs by neurons
support the hypothesis that neurons can modulate the
levels of oxidative modification. 
Formation of NFH-HNE adducts may be a novel protec-
tive mechanism in neurons regulated by phosphorylation/
dephosphorylation that serves to buffer the axon from
sudden spikes in toxic carbonyls. This mechanism may
work both in physiology and pathology for the clearance
of free radical products and in preventing cytoskeletal
abnormalities during the neurodegenerative process. KSP
repeats are likely to be one of the critical components per-
forming this regulation.
Animal models
Many animal models have contributed to the studies for
NFs in establishing NF subunit functions. The first model
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Figure 4. Hypothetical relationships among NF proteins, oxidative
stress, cell injury and tissue damage. NFs, especially NF-H as the
most abundant protein in neurons, may work as scavengers for 
oxidative stress, which protects other critical factors from oxidative
attack.
Figure 5. A hypothetical scheme for phosphorylation-dependent
HNE modification of neurofilament proteins. Phosphorylation may
be a regulatory factor which modulates the formation and clearance
of HNE adducts. Phosphorylation on serine residues renders the
lysine nearby more reactive to HNE molecules, and dephosphory-
lation abolishes formation of these products.
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is the Japanese quail discovered in 1991 (Quiverer) [156]
with a spontaneous mutation in NF-L at amino acid 114,
which is a nonsense mutant, that generates a truncated
protein of only 113 amino acids of NF-L out of total 556
amino acids and is incapable of forming NFs [126]. Homo-
zygous mutants contain no axonal NFs and exhibit mild
generalized quivering. In these animals, radial growth of
myelinated axons is severely attenuated [156], with con-
sequent reduction in axonal conduction velocity [127].
The second model is the transgenic mouse reported in
1994, expressing an NF-H/b-galactosidase fusion protein
in which the C-terminus of NF-H was replaced by b-ga-
lactosidase [129]. NF inclusions in the perikarya of neu-
rons, depletion of axonal NFs and reduced calibers were
found. Later on, Zhu et al. [29] showed that mice lacking
NFs due to a targeted disruption of the NF-L gene have
reduced axonal calibers and delayed maturation of regen-
erating myelinated axons. 
To demonstrate the NF subunit functions, we will only
compare NF subunit knockout and overexpressing mice
(table 2). To see more transgenic mice comparisons, other
reviews are recommended [46, 157].
NF-L knockout mice
The targeted disruption of the NF-L gene in mice con-
firmed the importance of NF-L in NF assembly [29]. 
NF-L knockout mice had no overt phenotype. In the ab-
sence of NF-L, the levels of NF-M and NF-H subunits are
dramatically decreased to ~5% of normal level and unable
to assemble into 10-nm filaments. As a result, these mice
have a scarcity of IF structures, severe axonal hypotrophy
and no large-sized myelinated axons [29]. Levels of other
cytoskeletons such as tubulin were increased, possibly 
as a compensating effect. While the NF-L gene knockout
mice provide definite proof that NFs are a major deter-
minant of axonal caliber, and NF-L is required for NF
formation, the specific roles of NF-M and NF-H sub-
units remain unclear. The reduced levels of NF-H and
NF-M in NF-L–/– mice are probably the result of an
enhanced proteolytic turnover of unassembled or disorgan-
ized NF proteins in the absenceof NF-L [29, 41, 145, 158].
NF-H knockout mice
Several laboratories have recently reported the character-
ization of NF-H null mice [71, 73, 90]. Surprisingly, the
absence of NF-H has little effect; the mice, the NF num-
ber and the caliber of motor axons during development
were all normal. With the C57Bl6 strain, Rao et al. [71]
and Zhu et al. [90] reported only a slight reduction in the
caliber of myelinated axons from the ventral roots of 
NF-H knockout mice; maybe the small changes are due to 
the increase of NF-M protein level and phosphorylation
levels. MTs increased twofold with little decrease in actin
level. In the mean time, the null mutant NF-H with 129J
strain mice described by Elder et al. [34] exhibited a more
pronounced reduction in the caliber of axons. Also, they
reported little difference in NF-L and NF-M levels. These
discrepancies are most likely attributable to differences in
the mouse genetic backgrounds. In any case, the com-
bined results suggest that NF-H has a minor effect on the
radial growth of axons and may be a key factor interact-
ing with MT/mf. 
NF-M knockout mice 
A clearer conclusion comes from the analysis of NF-M
knockout mice. Two independent studies have shown that
disruption of NF-M has a more severe effect than disrup-
tion of NF-H on the radial growth of large myelinated 
axons [31–33]. The absence of NF-M did not cause any
phenotypic changes in mice but caused an increase in
NF-H level and its phosphorylation. But the severe de-
creases in NF-L level (>50%) caused axonal NF content
decrease of more than 50%, resulting in axonal atrophy.
Compared with NF-H–/– mice, NF-M–/– mice showed
that NF-M is more critical in axonal radial growth.
NF-M/H double knockout mice
Moreover, double knockout mice lacking both NF-M 
and NF-H subunits showed hind-limb paralysis [32, 33].
The absence of NF-M/H causes the sequestering of un-
assembled NF-L proteins in the neuronal perikarya, no
NF formation in axons, twofold MT increase, and loss 
of ~24% of ventral root axons [32, 33]. The analysis of 
NF-M–/–, NF-H–/– double knockout mice demonstrates
that the high molecular weight subunits are required for
in vivo assembly of NFs and normal axonal growth. 
NF-L overexpressing mice
Studies in transgenic mice have found that overexpressing
mouse NF-L to ~4-fold leads to a striking ALS-like patho-
logy, in which most of the mice died before 3 weeks post-
natally with only 1/3 to 2/3 the body weight of normal
mice [137]. Also, strikingly, the only two mice surviving 
over 3 weeks finally recovered slowly to normality after 
9 months. The transgenic mice showed intensive NF ag-
gregation in all the compartments of neurons with de-
pleted rough endoplasmic reticulum (RER), neuronal de-
generation in both dorsal and ventral roots, phosphory-
lated NF-H in cell bodies and severe muscle atrophy,
which resembles the human ALS pathology. This study
confirmed that overexpression of NF-L and NF aggrega-
tion in mice can directly cause abnormality and degener-
ation of motor neurons.
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Table 2. Transgenic mouse models for NF subunit knockout or overexpression.
NF-L –/– NF-M –/– NF-H –/– NF-M/H –/– NF-L over- NF-M over- NF-H over-
expression expression expression 
(~4-fold) (~2-fold) (~1.2–4.5-fold)
Phenotype no no (limb no paralysis in mice died  no no
show impaired, hind limb before
may paralyze 3 weeks,  
later) motor neuron 
disease
Neuron no no no – yes no no
degeneration, 
loss
NF inclusion yes, in yes no no yes, massive yes, both in yes, both 
cell body cell body in cell body 
and axon and axon
Axonal no large decrease in no; smaller no large increase in decrease decrease 
caliber axons ventral roots; at the axons mediate level 50% 50%
changes 4 month beginning of NF-L; 
decrease 35% but normal decrease in  
and 2 years in adult higher level
decrease >70%
Axonal NF no NF;  <50% of  NF #; NF # no almost no  NF NF-H NF-M 
change ~5% of NF-L decrease; change;  NF; NF-L  accumulation decrease decrease
normal NF-H and NF-M and decrease
level of PO4-NF-H PO4-NF-M to ~20%
NF-M/H increase, increase, of normal 
left a-internexin a-internexin level
decrease decrease
Axonal IF MT and MT increase MT increase MT increase – – no
change GAP-43 a little ~2 fold; to 2 fold;
increase (1.35-fold) Tau increase; a-internexin 
actin decrease decrease
Axonal – increase to increase increase to – – decrease 
transport 2-fold 2-fold >2–3-fold
velocity 
of NF
Conduction decrease decrease decrease – – – –
velocity 70% 40% 40%
Indication NF-L is NF-M is NF-H is the NF-M/H are NF-L 4-fold NF-M NF-H 4.5-fold 
responsible more critical key factor needed for  overexpression overexpres- overexpression 
for NF in axonal to interact NF assembly  caused sion did did not cause  
formation caliber with MT in vivo   ALS-like not cause ND, so the 
than NF-H and actin and other disease; NF neuron slowing of  
key factors accumulation degenera- transport only 
needed to form can cause ND tion is not the 
long-range directly reason for ND
interaction
Reference [28, 72] [30–32, 72] [32, 72, 89] [30–32] [135] [136] [137]
The summary and comparison of NF subunit knockout and overexpression mouse models.
‘–’ means not found in the original papers.
NF-M overexpressing mice 
The NF-M overexpressing transgenic mice appeared
normal [138]. With ~2-fold increase in the total (WT plus
mutant) NF-M level in the mice, accumulation of NFs
was detected in cell bodies and axons. The axonal caliber
of neurons decreased ~50% with unchanged NF-L level
and 50% decrease of WT NF-H and WT NF-M levels.
This caliber reduction is a result of growth retardation
rather than total growth inhibition, which was restored to
the normal level with time, and it is correlated with reduc-
tion of WT NF-H and WT NF-M. No neuronal degenera-
tion was detected. Because the nearest interneurofilament
spacing did not change, this reduction may be strictly cor-
related with NF numbers. 
NF-H overexpressing mice 
Overexpressing 1.2- to 4.5-fold of WT NF-H in transgenic
mice showed no overt phenotypes or neuron loss [139,
175]. The level of NF-M in axons was correlatively reduced
with the increased NF-H level, and the NF-L level de-
creased 20%–40% in axons. Axonal caliber reduction
was correlated with the level of NF-H overexpression, and
>3-fold NF-H overexpression totally inhibited large axon
growth. This caliber reduction can also be considered as
strictly correlated with NF-M level or NF numbers.
In all these studies, only mice overexpressing >3-fold 
NF-L and NF-M/H double knockout mice showed severe
phenotypes. Taken together, these data clearly demon-
strate all the NF subunit functions: expression of NF-L is
responsible for NF assembly, and NF-M/H subunits are
required for NF assembly in vivo; NF-M is more critical
for axonal growth than NF-H, and the latter may be work-
ing as a key factor for NF interaction with other cyto-
skeletal polymers. The nearest interneurofilament spacing
does not change when NFs are presented in the axons, 
but to achieve the long-range ‘cross-bridges’, the side
chains of NF-H and other key factors are definitely re-
quired. Expression of NF-M and NF-H are coregulated 
in an inverse manner in motor axons, and they are com-
peting for transport and assembly with NF-L. In large-
caliber axons, microtubule content does not correlate
with axonal diameter as closely as does NF content 
[159, 160], but microtubule or other IFs are more signif-
icant in maintaining the diameter of medium- and small-
sized axons, where they are the major cytoskeletal com-
ponents. 
Notably, studies other than those above also provide solid
evidence for NF function. Recently, research on NF-H
truncated mutant mice [35] suggests that neither the 
C-terminal tail of NF-H nor its phosphorylation is impor-
tant for axonal caliber. Transgenic mice with human NF
subunits [161, 162] or mutations in mouse NFs [35, 163]
all showed severe motor neuron degeneration, which in-
dicates that non-WT NF forms may be the major factors
for neuronal degeneration. Also, studies with SOD mutant
mice which utilized human NF subunits provide addi-
tional important information [164–167].
NFs and neurodegenerative diseases
Abnormal accumulation of NFs is detected in many
human neurodegenerative disorders, including ALS, AD,
dementia with Lewy bodies, Parkinson disease and 
diabetes, among others. Many alterations can potentially
lead to accumulation of NFPs, including dysregulation 
of NFP synthesis, defective axonal transport, abnormal
phosphorylation and proteolysis. Studies in transgenic
mice also showed that NFs affect the dynamics and func-
tion of other cytoskeletal elements, such as microtubules
and actin filaments [90, 168]. It is widely believed that 
NF abnormalities in neurodegenerative disorders are the
hallmark of neuronal dysfunction. 
ALS 
ALS is a motor neuron disease, also called Lou Gehrig’s
disease, first identified in 1869 by the noted French neu-
rologist Jean-Martin Charcot. ALS affects as many as
20,000 Americans, with 5000 new cases occurring in the
United States each year, typically with an onset between
40 and 60 years of age. Men’s risk is about 1.5 times that
of women. ALS is usually fatal within 5 years after diag-
nosis. It is a progressive neurodegenerative disease that
attacks motor neurons in the brain and spinal cord. The
progressive degeneration of the motor neurons in ALS
eventually leads to neuron death and loss of related
muscle movements. Patients of ALS become partially or
totally paralyzed, but most of the patients’ cognitive func-
tions remain unaffected. There is no cure, but the Food
and Drug Administration (FDA) recently approved rilu-
zole, a drug that has been shown to prolong the survival
of ALS patients. 
A key neuropathological hallmark of ALS is intraneuro-
nal aggregates of NFs in degenerating motor neurons 
[75, 169–174]. Although the reason for the NF aggregates
is unclear, transgenic mouse models which overexpress
any of the NF subunits (NFL, NFM and NFH) will pro-
voke motor neuropathy characterized by the presence of
abnormal NF accumulations resembling those found in
ALS [137, 138, 165, 176]. Remarkably, motor neuro-
pathy in transgenic mice overexpressing human NF-H
was rescued by restoring a correct stoichiometry of NF-L
to NF-H subunits with the co-expression of human NF-L
transgene [167]. It hasbeen proposed that such alterations
in NF homeostasis are directly relevant to the pathogene-
sis of ALS [145]. 
Interestingly, abnormal NF inclusions are often asso-
ciated with decreases in levels of NF-L mRNA. NF-L
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mRNA is selectively reduced by up to 70% in degenerat-
ing neurons of ALS and AD [176–179]. A decrease in the
NF-L mRNA level occurs with a decrease of a-inter-
nexin or peripherin mRNA levels, suggesting an absolute 
alteration of the stoichiometry of NF expression in ALS
[177, 178]. 
Also, codon deletions or insertions in the KSP regions of
NF-H have been detected in a small number of sporadic
cases of ALS, including a large deletion of five KSP 
repeats [180–182]. Taken together, these observations sug-
gest a significant alternation in NF expression in ALS.
AD
AD is a CNS neurodegenerative disease. It was first
described in 1906 by German physician Dr Alois Alz-
heimer [6]. Although the disease was once considered
rare, it is now established as the leading cause of demen-
tia. An estimated 4 million individuals in the United
States have Alzheimer’s disease, with an annual expense
of about $70–$100 billion, and as many as 350,000 indi-
viduals develop the disease each year [183]. The risk of
AD varies from 12 to 19% for women over the age of 
65 years and 6 to 10% for men [184]. On average, AD 
patients live about 8 years after they are diagnosed, al-
though the disease can last for as many as 20 years. The
areas of the brain that control memory and thinking skills
are affected first, but as the disease progresses, cells die
in other regions of the brain. Eventually, the person with
AD will need complete care. If the individual has no other
serious illness, the loss of brain function itself will cause
death. There is no cure, and the only therapy known are
cholinesterase inhibitors or anti-cholinesterase drugs, 
including Reminyl (galantamine), Aricept (donepezil hy-
drochloride) and Exelon (rivastigmine), which provide
symptomatic relief but do little to slow disease progres-
sion. 
After the last 2 decades of intensive studies, more infor-
mation is available, but the cause of AD is still unknown.
Many hypotheses have been proposed, such as amyloid-b
cascade [185], tauopathy [186], inflammation [187, 188]
and oxidative stress [189–193].
Cytoskeleton disruption is a prominent feature and sec-
ondary event followed by oxidative damage in Alzheimer
disease [149, 168, 194]. NFT as the hallmark of AD is
composed of abnormally modified t, NFs and other cyto-
skeleton proteins. The cause for the aberrant biochemical
processes that transform normal t and NF into abnormal
filaments is not understood.  
In AD, inappropriate hyperphosphorylation of proteins
such as t and NF is prominent, which is likely due to per-
turbation in the balance between kinases and phosphatase
activities [195]. MAP kinase [196], GSK-3 [197] and
CDK 5 [198, 199] pathways are known to be involved in
t and NF phosphorylation in neurons. One of the earliest
changes noted in AD is accumulation of hyperphos-
phorylated t and NF in normal perikarya [74–77]. This
abnormal hyperphosphorylation may cause protein ag-
gregation in NFT in AD neurons. The role of NFT and
senile plaques in AD are still actively disputed.   
PD
PD is a progressive disorder of the CNS. The disease was
originally described in 1817 by an English physician,
James Parkinson, who called it shaking palsy. It affects
more than 1.5 million people in the United States. Men 
and women are similarly affected. The frequency of the
disease is considerably higher in the over-60 age group,
and the average duration of illness is about 9 years 
[200]. 
PD is caused by degeneration of the pigmented neurons
in the substantia nigra of the brain, resulting in decreased
dopamine availability. Clinically, the disease is charac-
terized by a decrease in spontaneous movements, gait 
difficulty, postural instability, rigidity and tremor. Only 
in the 1960s, however, were pathological and biochemical
changes in the brain of patients identified, opening the
way to the first effective medication for the disease. Ad-
ministration of the drug levodopa, a dopamine precursor,
has been the standard treatment for PD. 
The major pathological change of PD is an accumulated
protein inclusion called the Lewy body, composed of
numerous proteins, including the essential constituent of
a-synuclein protein, the three NF subunits [201], ubi-
quitin and proteasome subunits [202]. Electron micros-
copy and biochemical evidence indicate that the abnormal-
ly phosphorylated NFs form a non-membrane-bounded
compacted skein in the neuronal soma in the affected
neurons. 
In familial PD, mutations in the Parkin gene is the major
cause, in which over 20 different mutations have been
identified [203–206]. 
More recently, a point mutation has been reported in the
region of the NEFM gene coding for the rod domain 2B
of NF-M in an individual with PD [207]. The base pair
change results in substitution of serine for glycine at
residue 336, and probably disrupts assembly. The patient
developed PD at the very young age of 16. Although this
is an isolated report, and three other unaffected family
members also carried the mutation, it is possible that this
mutation is responsible for the young onset of an ag-
gressive form of PD. It is already known that mutations in
the same region of neurofilament proteins might cause a
peripheral motor nerve axonal loss in NEFL and central
dopaminergic loss in NEFM. It has also been found that
NF-L mRNA decreased in PD, correlating with the sever-
ity of the disease [208].
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Charcot-Marie-Tooth disease (CMT)
CMT is the most common inherited neurological disor-
der. It was discovered in 1886 by three physicians, Jean-
Marie-Charcot, Pierre Marie and Howard Henry Tooth.
Approximately 150,000 Americans are affected by the
condition. CMT affects both motor neurons and sensory
neurons to the muscles, and patients slowly lose normal
use of their feet/legs and hands/arms as nerves to the
extremities degenerate. The loss of nerve function in the
extremities also leads to sensory loss. The ability to dis-
tinguish hot and cold is diminished as well as the sense of
touch. There are several types of CMT, but the simplest
classification is into types 1, 2 and 3. Types 1 and 3 are
due to demyelinization, and type 2 is an axonal disease.
CMT is generally inherited in an autosomal dominant
pattern. At present there is no cure for CMT, although
physical therapy and moderate activity are often recom-
mended to maintain muscle strength and endurance. 
Several families have now been identified in which hetero-
zygosity for mutations of the NEFL gene on chromosome
8 are associated with CMT2 [209–212]. 
The first of these changes is a proline at residue 8 to glut-
amine. The second change is a leucine to a proline residue
at position 333 in the highly conserved rod domain 2B. 
These NEFL CMT2 mutations disrupt NF assembly and
axonal transport, and this probably underlies the disease
mechanism. A mouse model with a mutation in the same
coil, leucine to proline at residue 394, develops severe
selective motor neuron death because of disruption of
neurofilament assembly [163]. Georgiou et al. [211]
identified a novel NF-L missense mutation (Cys64Thr)
that caused the disease in a large Slovenian CMT2 family.
This mutation results in a proline-to-serine substitution 
at codon 22 (Pro22Ser), and the mutation showed complete
co-segregation with the dominantly inherited CMT2 
phenotype in this family. A similar Pro22Thr was also
detected in unrelated Japanese patients with CMT disease
[212, 213]. Jordanova et al. [212] found six pathogenic
missense mutations and one 3-bp inframe deletion in the
NF-L gene in 323 patients with different CMT pheno-
types. 
Some types of CMT are caused by defects in proteins
expressed in the Schwann cell, including the connexin 32
(CX32/GJB1) genes. Such mutations result in aberrant
myelination and altered NF phosphorylation. In such
cases, therefore, abnormalities of neurofilament phos-
phorylation occur downstream of the primary pathologi-
cal process but are still upstream of the end point. 
Diabetes
Diabetes is a disease in which the body does not produce
or properly use insulin. The cause of diabetes continues to
be a mystery, although both genetics and environmental
factors such as obesity and lack of exercise appear to play
roles. There are 18.2 million people in the United States,
or 6.3% of the population, who have diabetes. It is estim-
ated that at least 20.1 million Americans have pre-dia-
betes, in addition to the 18.2 million with diabetes. About
65% of deaths among people with diabetes are due to
heart disease and stroke. 
Diabetes is associated with a symmetrical distal axonal
neuropathy. The neuropathy is predominantly in sensory
neurons or dorsal root ganglia. The dorsal root ganglia of
rats with streptozocin-induced diabetes have an increase
in phosphorylation of NFs in lumbar dorsal root ganglia,
but not in other neural cell types [214]. This is probably
the result of activation of c-Jun N-terminal kinase (JNK),
which is a NF kinase. Pathologically, neurites from sym-
pathetic ganglia are swollen with disorganized aggregates
of NFs and other proteins, including peripherin [134].
Many of these studies show that NF abnormalities can be
primary causes of disease and that NF changes may not
simply be a passive marker of pathological processes. 
The neuropathy associated with diabetes includes well-
documented impairment of axonal transport, a reduction
in axon caliber and a reduced capacity for nerve regenera-
tion. All of those aspects of nerve function rely on the 
integrity of the axonal cytoskeleton. mRNAs for NFPs
are selectively reduced in the diabetic rat, and posttrans-
lational modification of at least one of the NFPs is alter-
ed. There is some evidence that altered expression of iso-
forms of protein kinases may contribute to these changes.
Tubulin and actin aberrant modifications are also found
[215].
The list of diseases involved with NF abnormalities will
likely increase, and the common mechanism for all the
protein aggregation diseases may soon be recognized [216].
Summary
In this review, we summarized as many as 11 aspects of
NF, which may provide some help for the overall knowl-
edge of the readers. Future studies will focus on func-
tions, interactions and pathology of NFs in normal axon
development and neurodegenerative diseases, which will
provide more knowledge and value for NFs. Hopefully, in
the near future, effective therapeutic methods for these
neurodegenerative diseases will be available for the
public.
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